Citations

Clear

1887 citation(s) found for "Thompson, P".

Intercellular adhesion molecule 1 links glioblastoma biology to a scalable prognostic model integrating clinical, imaging, and molecular features
Gandhi, Shreya, Ocaña-Tienda, Beatriz , Bettencourt, Manuel M., Singh, O, Devaraja, Kaviya , Irish, Emily R., Molina-García, David , Karimi, Shirin, Sosa, Julio , McIntyre, Ian, Gao, Andrew , Ramos-González, Ana, Asenjo, Beatriz , Flores-Rial, María Pino, Aldape, Kenneth , Santos, Carlos, Velásquez, Carlos, Mansouri, Alireza, Zadeh, Gelareh, Singh, Olivia S, Pérez-Beteta, Julián , Asenjo, Beatriz , Sánchez-Gómez, Pilar , Aldape, Kenneth D, Santos, Carlos , Mansouri, Alireza , Zadeh, Gelareh , Mansouri, Sheila , Mamatjan, Yasin , Hernández‐Laín, Aurelio , Drummond, Katharine Jann , Parney, Ian F. , Velásquez, Carlos , Mansouri, Alireza , Pérez‐García, Víctor M. , Mansouri, Sheila

Mayo Clinic

Neuro-Oncology Advances | July 10, 2026 | Volume: 8 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdag182 | PMID 42553785 Get It

Abstract Background Glioblastoma (GB) exhibits marked tumor microenvironmental heterogeneity, contributing to both therapy resistance and poor survival outcomes. Intercellular adhesion molecule 1 (ICAM1) is an inflammation-associated adhesion molecule implicated in immune-stromal interactions, but its clinical and biological significance in GB remains incompletely defined. Methods We performed ICAM1 immunohistochemistry, bulk RNA sequencing, DNA methylation analysis, single-nucleus RNA sequencing, and preoperative MRI-derived morphologic feature analysis across multi-institutional cohorts of treatment-naïve IDH-wildtype GB. Results High ICAM1 expression at both transcript and protein levels is associated with shorter overall survival, particularly within the mesenchymal transcriptional subtype. ICAM1 expression is inversely associated with promoter methylation. Single-nucleus RNA-sequencing analysis shows that ICAM1-high tumors are enriched for mesenchymal, hypoxia, stress-associated, and immunosuppressive myeloid programs, suggesting that ICAM1 reflects a multicompartment inflammatory tumor ecosystem. ICAM1 expression, tumor surface irregularity, and patient age are independently prognostic and minimally correlated, capturing complementary clinical, imaging, and molecular features of GB biology. When combined, our Clinical-Imaging-Molecular (CIM) framework refines outcome prediction across independent GB cohorts using routinely available clinical data, conventional imaging, and standard immunohistochemistry. Conclusions ICAM1 characterizes an immune-remodeled, stress-adapted GB ecosystem associated with poor clinical outcomes. Integrating patient age, surface irregularity, and ICAM1 expression yields a scalable and clinically accessible prognostic framework for GB, supporting tailored outcome prediction, particularly in low- and middle-resource settings without routine access to advanced molecular profiling.
Expanding Microgel Parameters to Model the Tumor Microenvironment and Examine Temozolomide Resistance in Glioblastoma
Payan, Brittany A. , Kattoor, Joel, Leon, Annika Carrillo Diaz De, Thompson, Gunnar, Molley, Tom, Sarkaria, Jann N., Harley, Brendan A.C. , Harley, Brendan A C , Thompson, Gunnar B. , Kilian, Kristopher Alan , Sarkaria, Jann N.

Mayo Clinic

No container title available | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.08.737105 | PMID 42465419 Get It

ABSTRACT Glioblastoma (GBM) is a highly aggressive brain tumor with a five-year survival rate of less than 5%. The current standard of care established 20 years ago includes maximal surgical resection and administration of alkylating agent temozolomide (TMZ). GBM is highly invasive, and GBM cells that evade surgical resection can become resistant to TMZ and develop new aggressive secondary tumors. Post-relapse there are few treatment options available to patients. Tissue engineering approaches suggest the opportunity to develop in vitro models of the GBM tumor microenvironment that may accelerate the discovery of novel therapies for GBM. Here, we report the adaptation of hydrogel microdroplets (microgels) to encapsulate GBM cells in a tailorable 3D matrix to assess patters of growth and to screen TMZ drug response using patient-derived xenograft (PDX) specimens. We exploit a unique aspect of the microgel system to account for the cellular heterogeneity within the tumor microenvironment (TME). We combine cell-laden microgels generated from TMZ-resistant and TMZ responsive variants of the same PDX specimens to create heterogeneous populations with varying levels of drug sensitivity. We demonstrate a range of drug resistance phenotypes as a function of the ratio of TMZ-responsive to resistance cells and identify the population required for TMZ-resistance to overtake take the response. We then investigate the influence of tumor mimetic shifts in hyaluronic acid bioavailability and hypoxia on patterns of TMZ resistance. We show exposure to matrix-bound hyaluronan increases TMZ resistance and the glioma stem cell population in both cell variants. Lastly, we report an increase in TMZ sensitivity but divergent changes in the GSC subfraction for TMZ resistant vs responsive GBM in the presence of hypoxia. Together, we demonstrate the versatility of cell-laden microgel approach to replicate heterogenous tumor populations, model shifts in the tumor microenvironment, and rapidly screen therapeutic response.
A systematic review and meta-analysis of pulmonary function in microgravity
Ghani, Fay, Cheung, Irene, Phillips, Anthony, Thompson, Bruce R. , Tawhai, M H, Ashworth, Edward, Thompson, Bruce , Ghani, Fay, Cheung, Irene Cheuk-Wai , Tawhai, Merryn Howatson , Ashworth, Edward Tom

Mayo Clinic

Gravitational and Space Research | July 8, 2026 | Volume: 14 | Issue: 1 | Pages: 53-75

10.2478/gsr-2026-0009 Get It

Abstract Technological advancements have increased the number of human spaceflights, including the advent of space tourism and deep space travel. The structure and function of the pulmonary system are gravitationally dependent, highlighting the importance of understanding functional changes within the pulmonary system during transient and sustained microgravity exposure. This systematic review and meta-analysis provide an overview of effects of microgravity (0G) on various functional outcome measures of the human lungs relative to Earth gravity (1G). Twenty-eight studies comprising parabolic flights (~20 seconds), short- (≤30 days) and long-duration spaceflight (>30 days) were assessed. Outcome measures reported in 1G (before flight) and 0G (in-flight) were extracted. Fixed effects models showed microgravity caused a reduction in elastic work and carbon dioxide production, and increases in pulmonary diffusion capacity, compliance, and pulmonary capillary blood volume. Despite this, the effect sizes were small and likely have little clinical significance in healthy individuals. However, they could impact space tourists who have lower health requirements for space travel, and those with underlying obstructive respiratory disorders. The results demonstrate how traditional functional pulmonary testing provides essential physiological benchmarks that complement high-throughput data collection methods, enabling an integrated understanding of how molecular changes translate into functional respiratory outcomes in microgravity.
Ventilator-Associated Pneumonia According to Chlorhexidine Oral Care Exposure in Patients With New Tracheostomy
Thompson, Hailey, Neiβ, A, Kooda, Kirstin, Shah, Aditya, Chalmers, Sarah, Cole, Kristin, Vollmer, Nicholas, Nei, Andrea, Kooda, Kirstin

Mayo Clinic

American Journal of Critical Care | July 3, 2026 | Volume: 35 | Issue: 4 | Pages: 289-297

10.4037/ajcc2026305 | PMID 42380032 Get It

Background Chlorhexidine is commonly used in prevention bundles for ventilator-associated pneumonia. Results for use of chlorhexidine in critically ill patients requiring mechanical ventilation via an endotracheal tube are mixed, and data for patients using a tracheostomy are lacking. Objectives To assess the risk for ventilator-associated pneumonia according to chlorhexidine exposure in patients requiring a new tracheostomy for mechanical ventilation. Methods This single-center, retrospective cohort study compared the development of ventilator-associated pneumonia according to chlorhexidine exposure in adult intensive care unit patients requiring new tracheostomy at a large academic medical center. Adults who received a new tracheostomy and required ventilator support for at least 48 hours were included. Patients treated for pneumonia at the time of tracheostomy or who met additional exclusion criteria were excluded. Results Of 235 patients who met the inclusion criteria, 203 received chlorhexidine and 32 did not. The cohort was predominantly White, male, and admitted to a surgical intensive care unit. Incidence of ventilator-associated pneumonia did not differ significantly between patients exposed or not to chlorhexidine (by 30 days, 32.5% vs 35.7%, P = .87). Time to development of ventilator-associated pneumonia also did not differ significantly between patients exposed or not (9 vs 12 days, respectively, P = .34). Conclusions Chlorhexidine exposure was not associated with a difference in the incidence of or time to ventilator-associated pneumonia after new tracheostomy. Further study is needed on the role of chlorhexidine in preventing ventilator-associated pneumonia after a new tracheostomy.
First-in-Human Safety and Feasibility of Nodal and Pedal MR Lymphangiography with Gadopiclenol
Thompson, Scott M. , Collins, Jeremy D. , Bendel, Emily C. , Reisenauer, Christopher J., Jundt, Michael C., Yalҫin, Müge, Favazza, Christopher , Lu, Aiming , McDonald, Robert J. , Williamson, Eric E. , Stinson, Eric G. , In, MyungHo, Favazza, Christopher P , Messina, Steven A , Collins, Jeremy , Williamson, Eric , Thompson, Scott , Bendel, Emily , In, Myung-Ho , Jundt, Michael C., In, Myung‐Ho , Messina, Steven A.

Mayo Clinic

Radiology: Cardiothoracic Imaging | July 2, 2026 | Volume: 8 | Issue: 4 | Pages: No page available

10.1148/ryct.260067 | PMID 42390347 Get It

Dynamic gadopiclenol-enhanced nodal and pedal MR lymphangiography was safe, with no adverse events, and feasible for imaging peripheral and central conducting lymphatic anatomy.
Idecabtagene vicleucel and endogenous T‐cell phenotypes linked to progression‐free survival in relapsed multiple myeloma
Paiva, Bruno , Manrique, Irene , Thompson, Ethan, CAMPBELL, TIMOTHY B., Guerrero, Camila, Martin, Nathan, Anderson, Larry D. , Lonial, Sagar, Raje, Noopur S., Lin, Yi, Moreau, Philippe, San-Miguel, Jesus, Munshi, Nikhil C., Kaiser, Shari, Paiva, Bruno , Anderson, Larry D , Thompson, Ethan G., Berdeja, Jesús G. , Lonial, Sagar , Moreau, Philippe , San-Miguel, Jesus , Munshi, Nikhil C.

Mayo Clinic

HemaSphere | July 2, 2026 | Volume: 10 | Issue: 7 | Pages: No page available

10.1002/hem3.70423 | PMID 42396130 Get It

Abstract Improved understanding of how chimeric antigen receptor (CAR) and endogenous T‐cell phenotypes associate with progression‐free survival (PFS) is needed to individualize and improve immunotherapy outcomes in multiple myeloma (MM). We characterized and investigated the prognostic value of immune dynamics defined with multidimensional and computational flow cytometry in 258 bone marrow aspirates from 107 MM patients treated with idecabtagene vicleucel in the KarMMa trial. At screening, there was an association between longer PFS and increased percentages of PD1 + cytotoxic T cells and ICOS − TIGIT + Tregs. At Month 1 after infusion, the presence of >1% CAR‐T cells, a CD4/CD8 CAR‐T‐cell ratio >0.09, and greater abundance of non‐activated non‐cytolytic CAR‐T cells identified patients with longer PFS. Notably, 47 of the 115 endogenous T‐cell clusters were prognostic at the latest assessment performed after CAR‐T infusion. Lower percentages of ICOS + TIGIT − Tregs showed the strongest association with longer PFS. Altogether, this large dataset of dynamic immune profiling throughout treatment with anti‐B‐cell maturation antigen (anti‐BCMA) CAR‐T cells uncovered that the T‐cell composition prior to apheresis as well as CAR‐T and endogenous T‐cell phenotypes after infusion associates with PFS. These findings have potential for translation into routine laboratory practice for improved understanding of response and resistance to CAR‐T cells in relapsed/refractory MM.
Neonatal Survival After Serial Amnioinfusions for Anhydramnios Due to Fetal Kidney Failure
Baschat, Ahmet A., Johnson, Anthony , Blumenfeld, Yair J., Schenone, Mauro H., Gebb, Juliana , Moldenhauer, Julie S., Zaretsky, Michael V. , Chmait, Ramen H., Gonzalez, Juan M., Rl, Miller, Krispin, Eyal , Shamshirsaz, A H A, Bligard, Katherine H. , Kalan, Amanda, Cortes, Magdalena Sanz, Bendel-Stenzel, Ellen, Menon, Shina , Wong, Cynthia, Kwak, Cecilia, Gallup, J Y, McKenna, Kristin, Marron, L, Tran, Cheryl L. , Behrendt, Nicholas, Galan, Henry L. , Samuels, Joshua, Swinford, Rita, Rosner, Mara, Kush, Michelle L, Nasr, Isam, Vasu, Samhita , Boss, Renee D. , Jelin, Angie C., Thompson, Richard E. , Davis, Jonathan M. , Warren, Daniel , Atkinson, Meredith A. , Gebb, Juliana S , Menon, Shina , Miller, Jena L. , Baschat, Ahmet , Blumenfeld, Yair J. , Schenone, Mauro H , Moldenhauer, Julie S. , Chmait, Ramen H. , Gonzalez, Juan, Cortes, Magdalena Sanz , Moon‐Grady, Anita J. , Bendel‐Stenzel, Ellen , Grimm, Paul, Marron, Leah, Hanna, Christian , Swinford, Rita D., Keiser, Amaris , Rosner, Mara , Nasr, Isam W. , Boss, Renee Denise , Jelin, Angie Child , Hanley, Daniel F.

Mayo Clinic

JAMA | July 1, 2026 | Volume: 336 | Issue: 6 | Pages: 473

10.1001/jama.2026.8568 | PMID 42384373 Get It

Importance Anhydramnios from fetal kidney failure causes lethal pulmonary hypoplasia. Serial amnioinfusions have shown promise in mitigating pulmonary disease from bilateral renal agenesis, but efficacy and safety for other causes of fetal kidney failure are unproven. Objective To assess the efficacy of serial amnioinfusions initiated before 26 weeks’ gestation to mitigate lethal pulmonary hypoplasia in cases of anhydramnios due to fetal kidney failure. Design, Setting, and Participants Prospective, nonrandomized clinical trial conducted at 13 US fetal therapy centers from December 2018 to February 2025. Outcomes for maternal-fetal pairs with anhydramnios before 22 weeks’ gestation due to fetal kidney failure without bilateral renal agenesis are reported; data collection for surviving infants continued until February 13, 2026. Exposure Thirty-two participants underwent serial amnioinfusions with isotonic fluid beginning before 26 weeks’ gestation. Main Outcomes and Measures The primary end point was neonatal survival for 14 days or longer with dialysis access placement. Secondary outcome measures of survival to discharge home and kidney transplant are reported. Results Twenty-nine of 32 participants (91%) had a live birth, with a median (IQR) gestational age at delivery of 34 weeks 1 day (31 weeks 5 days to 34 weeks 6 days). All participants delivered before 37 weeks’ gestation. No unexpected serious maternal adverse events occurred, and the most common maternal complications were preterm prelabor rupture of membranes in 19 participants (56%) and chorioamniotic separation in 10 (29%). The primary outcome occurred in 19 (65.5%) of 29 live-born neonates (95% CI, 45.7%-82.1%). Factors associated with survival to the primary outcome included receiving more amnioinfusions (median [IQR], 14 [9-18] in survivors vs 7 [4-11] in nonsurvivors; P = .01), longer time interval from first amnioinfusion to preterm prelabor rupture of membranes (63.5 [60.5-74.5] days in survivors vs 29.0 [22.0-56.0] days in nonsurvivors; P = .01), gestational age greater than 32 weeks (79% of survivors vs 38% of nonsurvivors; P = .03), and higher birth weight (2029 [1770-2250] g in survivors vs 1635 [1185-1915] g in nonsurvivors; P = .01). Fourteen live-born infants (48%) survived to hospital discharge at a median (IQR) age of 4.7 (3.4-5.7) months. Of the 11 infants surviving to date, 7 (64%) have undergone kidney transplant between ages 2 years to 5 years. Conclusions and Relevance Serial amnioinfusions mitigated lethal pulmonary hypoplasia in neonates with anhydramnios due to fetal kidney failure. Significant neonatal morbidity and mortality independent of early lung function was noted. Factors associated with survival were consistent with the Renal Anhydramnios Fetal Therapy trial’s bilateral renal agenesis cohort, suggesting common mechanistic pathways for mitigating pulmonary hypoplasia. Trial Registration ClinicalTrials.gov Identifier: NCT03101891
Abstract PR004: BTK A428D is a recurrent pan-resistance mutation to BTK degraders in clinical trials
Sievers, Quinlan, Lu, Hao, Cool, Allison , Grajewski, Stefan, Kong, Tim , Noviski, Mark, Mukerji, Ratul , Iuliano, James, Ye, Jordan , Rios, Mateo Sanchez Garcia de los, Bousquet, Hugo , Whelan, Sarah , Tan, May, Phelps, Christopher, Raman, Jahan, Notti, Ryan, Navarrete, Lizbeth Mendoza, Sekeres, Samantha, Lamkin, Eria, Bravo, Eduardo , Ewalt, Mark, Islam, Prioty , Mato, Anthony, Roeker, Lindsey, Taylor, Justin, Thompson, Meghan, Hansen, Gwenn, Abdel-Wahab, Omar, Sievers, Quinlan , Noviski, Mark , Mi, Xiaoli , Ficici, Emel , Iuliano, James N , Bousquet, Hugo, Notti, Ryan Q , Ewalt, Mark D. , Mato, Anthony R. , Roeker, Lindsey E. , Hansen, Gwenn M , Abdel‐Wahab, Omar

Mayo Clinic

Blood Cancer Discovery | June 24, 2026 | Volume: 7 | Issue: 3_Supplement | Pages: PR004-PR004

10.1158/2643-3249.lymphoma26-pr004 Get It

Abstract Early-phase clinical trials of BTK degraders in relapsed/refractory CLL have shown response rates of over 80%, including in patients with BTK mutations that confer resistance to conventional BTK inhibitors (BTKi). The molecular basis of resistance to BTK degraders is unknown and, given the promise of this class of drugs, would hold implications for therapy sequencing and the design of next-generation BTK degraders. To this end we identified five patients at Memorial Sloan Kettering who developed progressive disease while being treated on the phase 1 trials of zelebrudomide (NCT04830137, 4 patients) or bexobrutideg (NCT05131022, 1 patient). In two patients, one treated with zelebrudomide and the other with bexobrutideg, a pre-existing BTK A428D mutation had expanded at progression, rising from <1.5% at the start of treatment to >25%. In both cases, the increase in frequency of BTK A428D coincided with the loss of BTK degradation in peripheral blood B cells. No mutation in cereblon, the ligase utilized by these BTK degraders, was detected. To validate these clinical findings we generated wild-type and BTK A428D knock-in single-cell clones in TMD8 and HBL1 cells. BTK A428D conferred resistance to BTKi, including ibrutinib, acalabrutinib, zanubrutinib, and pirtobrutinib, as well as the clinical-stage BTK degraders zelebrudomide, bexobrutideg, BGB-16673, and AbbVie-1 (Compound 1, WO 2023183811). BTK A428D’s pan-resistance is unique compared to previously studied BTKi resistance mutations which remain susceptible to at least one BTKi and all clinical-stage BTK degraders tested. To understand how BTK A428D confers pan-resistance to BTKi and BTK degraders we conducted surface plasmon resonance studies which demonstrated that BTKi and all four clinical-stage BTK degraders tested are unable to bind BTK A428D. We next solved the crystal structure of apo BTK A428D to 1.8Å, which revealed that the mutant aspartate, which is larger and negatively charged compared to the wild-type alanine, sterically blocks BTKi and degraders from accessing residues in the hinge region of the kinase that are required for drug binding. We next asked why BTK A428D, despite conferring pan-resistance, has only been detected in 1.1% of patients treated with BTK inhibitors. Intriguingly, we noted that in one of our index patients, the frequency of BTK A428D declined and became undetectable after the withdrawal of zelebrudomide, suggesting a fitness defect. To assess this hypothesis, we compared the proliferation rates of five TMD8 wild-type and five BTK A428D single-cell clones; the BTK A428D clones grew more slowly and were consistently outcompeted in mixing studies. In summary, low-frequency BTK A428D mutations can expand under the selection pressure of BTK degraders and confer clinical resistance by preventing drug binding. The mutation, however, is outcompeted in the absence of BTK-targeted therapies. These findings provide rationale for the investigation of combination therapies and the development of next-generation BTK degraders capable of circumventing BTK A428D. Citation Format: Quinlan Sievers, Hao Lu, Allison Cool, Stefan Grajewski, Tim Kong, Mark Noviski, Xiaoli Mi, Emel Ficici, Ratul Mukerji, James Iuliano, Jordan Ye, Mateo Sanchez Garcia de los Rios, Hugo Bousquet, Sarah Whelan, May Tan, Christopher Phelps, Jahan Raman, Ryan Notti, Lizbeth Mendoza Navarrete, Samantha Sekeres, Eria Lamkin, Eduardo Bravo, Mark Ewalt, Prioty Islam, Anthony Mato, Lindsey Roeker, Justin Taylor, Meghan Thompson, Gwenn Hansen, Omar Abdel-Wahab. BTK A428D is a recurrent pan-resistance mutation to BTK degraders in clinical trials [abstract]. In: Proceedings of the Fifth AACR International Meeting on Advances in Malignant Lymphoma: From Discovery to Clinical Impact; 2026 Jun 24-27; Philadelphia, PA. Philadelphia (PA): AACR; Blood Cancer Discov 2026;7(3_Suppl):Abstract nr PR004.
No Association of Prior Administration of Selected Vaccines with Lymphoma Prognosis
Cholack, George , Hinder, Verena , Mwangi, Raphael , Habermann, Thomas M. , Robinson, Dennis P. , Larson, Melissa C. , Feldman, Andrew L. , Witzig, Thomas E. , Ansell, Stephen M. , Thompson, Carrie A. , Novak, Anne J. , Witzig, T.E. , Cholack, George A , Mou, Eric , Wang, Yucai , Thompson, Carrie A , Maurer, Matthew , Novak, Anne J , Slager, Susan L , Cerhan, James R , Feldman, Andrew L , Habermann, Thomas , Larson, Melissa C , Mou, Eric , Wang, Yucai , Maurer, Matthew J. , Slager, Susan L. , Cerhan, James R.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: OF1-OF3

10.1158/1055-9965.epi-26-0427 | PMID 42340351 Get It

Abstract Background: Although some vaccines seem to be associated with a lower risk of lymphoma, their impact on outcomes is largely unknown. Methods: Data from a large prospective lymphoma cohort study were utilized to estimate associations of self-reported history of vaccination against hepatitis A, hepatitis B, influenza, and yellow fever with event-free survival (EFS) and overall survival (OS) using Cox proportional hazard models. Results: None of the vaccines were associated with EFS [hazard ratio (HR) 0.77–1] or OS (HRs 0.96–1.04). Similarly, there were no significant associations between the vaccines and outcomes for each lymphoma subtype. Conclusions: Prior vaccination against selected viruses was not associated with EFS or OS among patients with lymphoma. Impact: We did not find evidence for an impact of prior vaccination on lymphoma prognosis.
ID #759 Outcomes following focal proton therapy for non-metastatic intracranial atypical teratoid/rhabdoid tumor (ATRT)
Indelicato, Daniel, Mailhot-Vega, Raymond, Thompson, Elizabeth , Johnson, Bryan, Morris, Chris, Klawinski, Darren, Ranalli, Nathan, Bradley, J R, Vega, Raymond B. Mailhot , Mailhot Vega, Raymond B , Klawinski, Darren , Ranalli, Nathan J.

Mayo Clinic

Neuro-Oncology Pediatrics | June 24, 2026 | Volume: 2 | Issue: Supplement_1 | Pages: No page available

10.1093/neuped/wuag026.319 Get It

Abstract Background In children with non-metastatic atypical teratoid/rhabdoid tumor (ATRT), proton therapy is increasingly utilized worldwide due to the radiosensitivity of afflicted young patients. General questions persist, however, surrounding dose and volume of radiotherapy. Methods Between 2009-2024, 39 children from a single institution with non-metastatic intracranial ATRT received focal proton therapy at a median age of 2.4 years (range 0.7-19). Twenty-two patients had supratentorial tumors and 27 had gross/near total resection prior to radiation. Most common chemotherapy regimens were ACNS0333 and SJYC07 (n = 10 each) and Dana-Farber (n = 6). Four patients received consolidative high-dose chemotherapy after radiation. The median radiation dose was 50.4 Gy (range, 50.4-54). The cumulative incidence method assessed freedom from selected endpoints.The Fine-Gray method assessed the level of statistical significance between levels of selected prognostic factors. Results With a median followup of 5.2 years (range 0.5-16.2), the 5-yr overall survival, progression-free survival, and local control was 63%, 64%, and 97%, respectively. Thirteen patients developed isolated leptomeningeal failure as first site of recurrence. Only subtotal resection was significantly associated with local recurrence (100% vs 92%, p < 0.05). Patient age, tumor site, extent of resection, radiation dose, and chemotherapy regimen were otherwise not significantly associated with disease control or survival. Four patients experienced symptomatic radiation necrosis, including 1 death: Three of 4 cases received 54 Gy and consolidative intrathecal methotrexate (n = 2) or high dose ACNS0333 intravenous chemotherapy (n = 1, fatal) after radiation. The other patient received 50.4 Gy and necrosis was immediately preceded by ventriculoperitoneal shunt failure. Six patients developed hearing loss requiring aids. One patient developed radiation-induced meningioma a decade following treatment. Conclusion This represents the largest experience reporting 5-year outcomes following focal radiation in children with non-metastatic intracranial ATRT. When applied with a variety of modern chemotherapy regimens in real-world settings, focal proton therapy at a dose of 50.4 Gy may offer the best therapeutic ratio but does not eliminate serious toxicity. If avoidance of craniospinal radiation remains an ongoing priority, further improvement in survival will depend upon systemic therapy.